Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients.
about
Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003Susceptibility of filamentous fungi to voriconazole tested by two microdilution methodsAspergillus infections in transplant recipients.Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.Regulatory circuitry governing fungal development, drug resistance, and disease.Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus.In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus sppUse of terbinafine in rare and refractory mycoses.Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistanceWhen primary antifungal therapy fails.Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis?Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation.Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era.Molecular Tools for the Detection and Deduction of Azole Antifungal Drug Resistance Phenotypes in Aspergillus Species.Mycological Profile and Antifungal Susceptibility of Fungal Isolates from Clinically Suspected Cases of Fungal Rhinosinusitis in a Tertiary Care Hospital in North India.Widespread amphotericin B-resistant strains of in Hamilton, Canada
P2860
Q30981454-49EB331D-4C39-4749-8F43-7B3171E67265Q33592487-B7C53A52-253D-46CF-9CB3-2C21B24ACC94Q33719294-F0AB8526-4D88-4202-955D-C1720DB5559DQ33857685-E46F4240-B401-4B22-90CD-B1CEDDC0364FQ34190284-DD3B49B6-22C7-4E5F-A4ED-69B82B1D03CCQ34452089-DFA84C2D-3268-461C-B2EE-7AAD4354C2F7Q36171554-8C0C5E27-70CB-49FB-8FCB-5742B1D31E00Q37071133-B66E0DA6-1ED6-45CB-AF2E-75BE732FE2A9Q37122826-86E8A92C-5230-4A20-9421-2D2FB9ECEB8CQ37141191-03A6017D-A524-4371-AA75-0075ADE29F73Q37859397-5451F3AA-1B2E-4DD0-9F9D-D417AC0A5C3EQ41847739-5344A1BF-5C70-46DE-AEE0-0137F33DC16EQ42446554-3886FAA9-55AB-43FC-A5FA-F6913C6F2479Q46307503-A7938707-AFF6-46D5-A07A-524FA1159BDBQ46768709-F17A5B57-8A70-480F-A7DB-55F707E271DCQ57071871-AD274C8D-0130-4068-8D3F-E8B9C87DC6C2
P2860
Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Susceptibility testing of sequ ...... covered from treated patients.
@en
Susceptibility testing of sequ ...... covered from treated patients.
@nl
type
label
Susceptibility testing of sequ ...... covered from treated patients.
@en
Susceptibility testing of sequ ...... covered from treated patients.
@nl
prefLabel
Susceptibility testing of sequ ...... covered from treated patients.
@en
Susceptibility testing of sequ ...... covered from treated patients.
@nl
P2093
P356
P1476
Susceptibility testing of sequ ...... ecovered from treated patients
@en
P2093
Bernadette Lebeau
EBGA Network
Françoise Symoens
Joseph Meletiadis
Maria-Anna Viviani
Marie-Antoinette Piens
Nicole Nolard
Paul E Verweij
Renée Grillot
P304
P356
10.1099/JMM.0.05326-0
P577
2004-02-01T00:00:00Z